TrialBreast (Edinburgh, Scotland)2020

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.

Peter A Fasching et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.